French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
Recruiting · NCT06837454 · Observational (researchers observe without assigning treatment) · Lead sponsor: Sanofi
View the official record on ClinicalTrials.gov →What this trial is about
The objective of the study is to describe the therapeutic management of patients more than or equal to 18 years old eligible for systemic therapy or treated by systemic therapy for atopic dermatitis (AD). This study will be proposed to a sample of French dermatologists experienced in the management of AD, practicing in hospital centers and/or office-based dermatologists. The study will be conducted in real conditions of practice, systemic treatment decisions will be taken at the sole initiative of the participating physician irrespective of the patient enrollment decision. Each patient will be followed-up in routine care setting for 1 year.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Signed informed consent form.
- Patient with moderate to severe AD according to the Investigator's judgment and
- Patient eligible to systemic treatment as Atopic Dermatitis Control Tool (ADCT) more than or equal to (≥) 7 and/or use topical corticosteroids (TCS) more than (\>) 90 gram (g)/month and/or TCS are not advisable.
- Patient currently under systemic treatment.
- Able to understand and complete study-related questionnaires.
Exclusion criteria
- Any condition that, in the opinion of the Investigator, may interfere with patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from adequately completing, as per routine care, the schedule of visits and assessments
- Patient receiving systemic therapy only for a disease other than AD.
- Patient participating in any interventional clinical trial at the time of enrolment.
- Patient is under tutorship or curatorship; patient under safeguard of justice or deprived of his/her liberty by an administrative or court decision
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Where it is running
60 locations listed.
- Investigational Site Number: 2500051 - Aix-en-Provence, France
- Investigational Site Number: 2500023 - Amiens, France
- Investigational Site Number: 2500004 - Angers, France
- Investigational Site Number: 2500017 - Angers, France
- Investigational Site Number: 2500050 - Arès, France
- Investigational Site Number: 2500063 - Arès, France
- Investigational Site Number: 2500054 - Bayonne, France
- Investigational Site Number: 2500043 - Bezannes, France
- Investigational Site Number: 2500040 - Biarritz, France
- Investigational Site Number: 2500036 - Bordeaux, France
- Investigational Site Number: 2500053 - Bordeaux, France
- Investigational Site Number: 2500013 - Chalon-sur-Saône, France
- Investigational Site Number: 2500026 - Chalon-sur-Saône, France
- Investigational Site Number: 2500046 - Chalon-sur-Saône, France
- Investigational Site Number: 2500018 - Cherbourg, France
- Investigational Site Number: 2500020 - Cholet, France
- Investigational Site Number: 2500041 - Châlons-en-Champagne, France
- Investigational Site Number: 2500048 - Clermond Ferrand, France
- Investigational Site Number: 2500059 - Contamine-sur-Arve, France
- Investigational Site Number: 2500010 - Dunkirk, France
- Investigational Site Number: 2500047 - Estrées-Deniécourt, France
- Investigational Site Number: 2500049 - Fort-de-france, France
- Investigational Site Number: 2500032 - La Ravoire, France
- Investigational Site Number: 2500044 - La Ravoire, France
- Investigational Site Number: 2500011 - La Roche-sur-Yon, France
- Investigational Site Number: 2500037 - La Tronche, France
- Investigational Site Number: 2500056 - Le Mans, France
- Investigational Site Number: 2500068 - Le Mans, France
- Investigational Site Number: 2500001 - Le Mans, France
- Investigational Site Number: 2500012 - Le Puy-en-Velay, France
- Investigational Site Number: 2500003 - Limoges, France
- Investigational Site Number: 2500031 - Loperhet, France
- Investigational Site Number: 2500060 - Marseille, France
- Investigational Site Number: 2500055 - Monaco, France
- Investigational Site Number: 2500070 - Mont-Saint-Aignan, France
- Investigational Site Number: 2500058 - Mont-de-Marsan, France
- Investigational Site Number: 2500033 - Niort, France
- Investigational Site Number: 2500065 - Paris, France
- Investigational Site Number: 2500005 - Paris, France
- Investigational Site Number: 2500030 - Paris, France
- Investigational Site Number: 2500071 - Paris, France
- Investigational Site Number: 2500009 - Paris, France
- Investigational Site Number: 2500028 - Périgueux, France
- Investigational Site Number: 2500027 - Périgueux, France
- Investigational Site Number: 2500029 - Rennes, France
- Investigational Site Number: 2500035 - Rennes, France
- Investigational Site Number: 2500021 - Romans-sur-Isère, France
- Investigational Site Number: 2500022 - Rouen, France
- Investigational Site Number: 2500025 - Saint-Etienne, France
- Investigational Site Number: 2500062 - Saint-Gervais-les-Bains, France
- Investigational Site Number: 2500076 - Saint-Martin, France
- Investigational Site Number: 2500034 - Saint-Maur-des-Fossés, France
- Investigational Site Number: 2500008 - Saint-Maur-dès-Faussés, France
- Investigational Site Number: 2500045 - Saint-Quentin, France
- Investigational Site Number: 2500057 - Sainte-Eulalie, France
- Investigational Site Number: 2500019 - Sainte-Maxime, France
- Investigational Site Number: 2500015 - Toulouse, France
- Investigational Site Number: 2500016 - Tours, France
- Investigational Site Number: 2500038 - Vannes, France
- Investigational Site Number: 2500024 - Villefranche-sur-Saône, France
Showing 60 of 62 listed sites. See the official record for the complete list.
Read the full protocol, contacts and eligibility on ClinicalTrials.gov →